Please login to the form below

Not currently logged in
Email:
Password:

aspirin

This page shows the latest aspirin news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca’s Brilinta reduces rate of secondary stroke

AstraZeneca’s Brilinta reduces rate of secondary stroke

Detailed results from the phase 3 THALES trial also showed that Brilinta, given at a dose of 90mg twice-daily alongside aspirin, significantly reduced the rate of ischaemic stroke by 21%, ... The drug also reduced the risk for severe bleeding events –

Latest news

  • AZ says Brilinta hits the mark in new stroke trial AZ says Brilinta hits the mark in new stroke trial

    This time round, AZ evaluated Brilinta (ticagrelor) at a dose of 90-mg twice-daily, taken with aspirin for 30 days, in the phase 3 THALES trial. ... AZ has already tried to prove Brilinta’s benefit over aspirin in preventing stroke, but failed to do so

  • AZ unveils phase 3 Brilinta data in CAD and type 2 diabetes AZ unveils phase 3 Brilinta data in CAD and type 2 diabetes

    The study demonstrated that Brilinta plus aspirin reduced the risk of cardiovascular death, heart attack or stroke by 10% compared to aspirin alone.

  • AZ says Brilinta hits the mark in diabetic heart disease AZ says Brilinta hits the mark in diabetic heart disease

    The study showed that in diabetics with CAD and no prior history of heart attack or stroke, Brilinta given on top of aspirin therapy achieved a statistically-significant reduction in a ... Last year, the GLOBAL LEADERS study last year also showed that

  • Xarelto no better than aspirin in secondary stroke study Xarelto no better than aspirin in secondary stroke study

    low-dose aspirin, which is commonly prescribed for this purpose, but failed to hit the mark at the interim stage. ... While bleeding rates were low overall, an increase in bleeding was observed in the rivaroxaban arm compared to the low dose aspirin arm,

  • Xarelto beats aspirin for recurrent blood clots Xarelto beats aspirin for recurrent blood clots

    A new phase III trial shows that Bayer and Janssen's novel oral anticoagulant (NOAC) Xarelto is more effective than aspirin at preventing recurrent blood clots, with no increase in bleeding ... It's already known that after an initial few months of

More from news
Approximately 1 fully matching, plus 71 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • Natasha Giordano joins PLx Pharma Natasha Giordano joins PLx Pharma

    We are confident Natasha will be a driving force for PLx as we transition from the development phase to the commercial launch of our lead product, PL2200 Aspirin.”. ... I look forward to building on the compelling clinical data and initial market

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....